FENNEC PHARMACEUTICALS INC.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.9M | $15.1M | $13.8M | $12.5M | $9.7M | $8.8M | $7.9M | $7.0M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $118.0K | $49.0K | $20.0K | $29.0K | $107.0K | $94.0K | $50.0K | $97.0K |
| SG&A Expense | $4.6M | $3.2M | $9.2M | $6.8M | $6.5M | $5.9M | $4.2M | $6.1M |
| Operating Income | $1.7M | $-119.0K | $-2.6M | $-189.0K | $-2.7M | $-808.0K | $-934.0K | $-5.2M |
| Operating Margin | 9.7% | -0.8% | -18.5% | -1.5% | -28.3% | -9.2% | -11.8% | -74.6% |
| Interest Expense | $3.0K | $7.0K | $308.0K | $586.0K | $594.0K | $592.0K | $966.0K | $1.0M |
| Pretax Income | $2.0M | — | — | — | $-3.2M | — | — | — |
| Income Tax Expense | $42.0K | — | — | — | — | $0 | — | — |
| Net Income | $2.0M | $201.0K | $-4.8M | $-638.0K | $-3.2M | $-1.2M | $-2.0M | $-5.7M |
| Net Margin | 11.0% | 1.3% | -34.7% | -5.1% | -32.7% | -13.3% | -25.0% | -82.2% |
| EPS (Basic) | $0.06 | $0.01 | $-0.17 | $-0.02 | $-0.11 | $-0.04 | $-0.08 | $-0.21 |
| EPS (Diluted) | $0.05 | $0.01 | $-0.17 | $-0.02 | $-0.11 | $-0.04 | $-0.02 | $-0.21 |
| Shares Outstanding (Basic) | 34.5M | 34.3M | 28.6M | 27.9M | 27.7M | 27.6M | 27.3M | 27.4M |
| Shares Outstanding (Diluted) | 36.4M | 35.5M | 28.6M | 27.9M | 27.7M | 27.6M | 27.3M | 27.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |